http://test.pharmabiz.com/news/pfizer-to-acquire-serenex-43788 Web'Serenex, Inc Company Profile' is a complete analysis of the company's operations, strategies, outlook and historic performance. The research work analyzes key strategies …
EydisBio
Web22 Apr 2010 · The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, … Web16 Jan 2008 · Serenex, Inc. Information provided by: Esanex Inc. Study Details ; Tabular View; No Results Posted; Disclaimer; How to Read a Study Record; Study Description. ... Inc. ClinicalTrials.gov Identifier: NCT00595686 Other Study ID Numbers: B1311002 SNX-5422-CLN1-002 : First Posted: January 16, 2008 Key Record Dates: Last Update Posted: May 17, … tennis lessons las vegas
Steve Hall - board_member @ Nimbus Therapeutics - Cointime
WebIn 2003, he joined Serenex Inc. as Senior Director of Structural Chemistry and Informatics, and in 2008, Serenex was acquired by Pfizer for its proteomics platform and drug … WebSNX-5422 is originally developed by Pfizer and Serenex, Inc., and the phase I clinical trials for it has been completed in the treatment of solid tumors. Although the mechanism of action remains to be fully elucidated, SNX-5422, which is a prodrug, is rapidly converted to SNX-2112 that accumulates in tumors relative to normal tissues. ... http://www.ipaustralia.com.au/applicant/serenex-inc/patents/AU2002364063/ tennis m2000